Login / Signup

Engineered immunogen binding to alum adjuvant enhances humoral immunity.

Tyson J MoyerYu KatoWuhbet AbrahamJason Y H ChangDaniel W KulpNicki WatsonHannah L TurnerSergey MenisRobert K AbbottJinal N BhimanMariane B MeloHayley A SimonSara Herrera-De la MataShu LiangGrégory SeumoisYash AgarwalNa LiDennis R BurtonAndrew B WardWilliam R SchiefShane CrottyDarrell J Irvine
Published in: Nature medicine (2020)
Adjuvants are central to the efficacy of subunit vaccines. Aluminum hydroxide (alum) is the most commonly used vaccine adjuvant, yet its adjuvanticity is often weak and mechanisms of triggering antibody responses remain poorly understood. We demonstrate that site-specific modification of immunogens with short peptides composed of repeating phosphoserine (pSer) residues enhances binding to alum and prolongs immunogen bioavailability. The pSer-modified immunogens formulated in alum elicited greatly increased germinal center, antibody, neutralizing antibody, memory and long-lived plasma cell responses compared to conventional alum-adsorbed immunogens. Mechanistically, pSer-immunogen:alum complexes form nanoparticles that traffic to lymph nodes and trigger B cell activation through multivalent and oriented antigen display. Direct uptake of antigen-decorated alum particles by B cells upregulated antigen processing and presentation pathways, further enhancing B cell activation. These data provide insights into mechanisms of action of alum and introduce a readily translatable approach to significantly improve humoral immunity to subunit vaccines using a clinical adjuvant.
Keyphrases
  • early stage
  • immune response
  • lymph node
  • single cell
  • stem cells
  • artificial intelligence
  • deep learning
  • rectal cancer
  • case report
  • data analysis
  • amino acid
  • neoadjuvant chemotherapy